Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Multivalent Opioid Conjugate Vaccines for Opiate Addiction Treatment

Technology #20120281

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
Multivalent Opioid VaccineAnti-AddictionOpioid Addiction
Categories
Researchers
Philip S. Portoghese, PhD
Medicinal Chemistry, College of Pharmacy
External Link (www.pharmacy.umn.edu)
Morgan Le Naour, PhD
Medicinal Chemistry, College of Pharmacy
External Link (profiles.ahc.umn.edu)
Paul Pentel, MD
Hennepin County Medical Center
External Link (hcmcmn.org)
Marco Pravetoni, PhD
Hennepin County Medical Center
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

US Patent Pending 2014-0093525
Publications
Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats
Vaccine, 29 June 2012, Pages 4617-4624
An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia
Journal of Pharmacology and Experimental Therapeutics, 2012 Apr;341(1):225-32

Anti-Addiction Conjugate Vaccine Treats Opiate Dependence

The multivalent “anti-addiction” conjugate vaccine produces drug-specific antibodies that sequester the target drug in serum and extracellular fluids, thus reducing drug distribution to the brain. A multivalent method is proposed in which anti-addiction vaccines against specific opioids are combined based on the specific drugs being abused. The conjugate vaccine cannot be abused and ensures longer duration of action and thus fewer expected non-compliance issues. Since the technology can encompass various opioid drug addictions and is low risk, the patient pool is increased when compared to other anti-addiction treatments.

MN-IP Try and Buy
Try
  • Trial period: 12 to 18 months. $5000/6 months.
  • Fee waived if MN-based company or if sponsoring $50,000+ in research.
Buy
  • Exclusive license for a $15,000 conversion payment.
  • Additional patent expenses due.
  • 3% royalty after $1 million of product sales.
  • Discount for MN companies.

** View the Term Sheet **
** Contact Rebecca Gerber for specific details. **

Current Opioid Addiction Treatment

Nearly 2,000,000 people in the U.S. are addicted to opioid pain relievers and an additional 350,000 are addicted to heroin. While current treatments for opioid addiction are effective, therapy with opioid agonist methadone and partial agonist buprenorphine have drawbacks such as the need for supervision, risk of abuse, non-compliance, and patient eligibility. Antagonist therapy with naltrexone is limited by lack of agonist effects, non-compliance, and increased risk of withdrawal symptoms. As a result, fewer than 1 in 5 opioid addicts or abusers in the U.S. are willing to use these medications. A need exists for an anti-addiction treatment that reduces relapse rates, decreases non-compliance risk, expands patient eligibility, and cannot be abused.

BENEFITS OF THIS MULTIVALENT APPROACH TO AN ANTI-ADDICTION CONJUGATE VACCINE:

  • Less risk of compliance issue
  • Fewer visits to clinics during treatment process
  • Treatment cannot be abused
  • Creation of a cocktail vaccine that best addresses patients’ specific addictions
  • Lower risk of relapse due to use of antibodies
  • Larger patient pool as varying addictions may be treated